GeoVax Announces Addition to Its Board of Directors
01 September 2022 - 11:00PM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing human vaccines and immunotherapies
against infectious diseases and cancer, announced today that it has
appointed Nicole Lemerond, CFA, to its Board of Directors.
Nicole Lemerond is a financial executive with over 25 years of
experience in investment management, private equity, investment
banking, mergers/acquisitions, and leveraged finance. She has
significant experience executing complex transactions, managing
diligence processes, raising capital and structuring balance
sheets. Her breadth of industry expertise includes providers,
payors, medical device manufacturers, HCIT providers,
pharmaceutical and life sciences companies.
Throughout her career, Ms. Lemerond has worked with public and
private company management teams and boards to increase stakeholder
value. She established and led healthcare groups at leading
investment firms and has also worked at several large financial
institutions, including Lehman Brothers and The Carlyle Group. Ms.
Lemerond holds a Bachelor of Science degree from Cornell University
and is a CFA charter holder.
David Dodd, GeoVax Chairman and CEO, commented, “Ms. Lemerond
brings a wealth of experience to GeoVax, and we are very pleased to
have Nicole join our Board. Her knowledge and experience in
healthcare finance will be a tremendous asset to us as we
accelerate GeoVax’s product development portfolio towards
regulatory registration and commercialization.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing human vaccines and immunotherapies against infectious
diseases and cancer using novel proprietary platforms. GeoVax’s
product pipeline includes two ongoing Phase 2 clinical trials of
GEO-CM04S1 for COVID-19 as a universal booster vaccine to mRNA
vaccines authorized by the U.S. Food and Drug Administration (FDA)
and as a primary vaccine for use in immunocompromised patients. In
addition to GEO-CM04S1 for COVID-19, GeoVax is developing GEO-CM02
as a pan-coronavirus vaccine. The Company is also conducting a
Phase 1/2 clinical trial of Gedeptin® for treatment of head and
neck cancer. Gedeptin® has been granted orphan drug status by the
FDA. Additional research and development programs include
preventive vaccines against Zika Virus, hemorrhagic fever viruses
(Ebola, Sudan, Marburg, and Lassa) and malaria, as well as
immunotherapies for multiple solid tumors. The Company’s portfolio
of wholly owned, co-owned, and in-licensed intellectual property
stands at over 70 granted or pending patent applications spread
over 20 patent families.
For additional information about GeoVax, visit our website:
www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding
GeoVax’s business plans. The words “believe,” “look forward to,”
“may,” “estimate,” “continue,” “anticipate,” “intend,” “should,”
“plan,” “could,” “target,” “potential,” “is likely,” “will,”
“expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventative vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventative vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventative vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventative vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is contained in our
periodic reports on Form 10-Q and Form 10-K that we have filed and
will file with the SEC. Any forward-looking statement made by us
herein speaks only as of the date on which it is made. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
Contact:GeoVax Labs,
Inc.investor@geovax.com678-384-7220
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Apr 2024 to May 2024
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From May 2023 to May 2024